Rajeev Saggar Sells 71,381 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 71,381 shares of the stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $27.00, for a total value of $1,927,287.00. Following the completion of the sale, the insider owned 176,549 shares in the company, valued at approximately $4,766,823. This trade represents a 28.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Rajeev Saggar also recently made the following trade(s):

• On Monday, October 13th, Rajeev Saggar sold 5,327 shares of Liquidia stock. The shares were sold at an average price of $23.41, for a total transaction of $124,705.07.
• On Thursday, August 28th, Rajeev Saggar sold 20,000 shares of Liquidia stock. The shares were sold at an average price of $27.85, for a total transaction of $557,000.00.
• On Thursday, August 28th, Rajeev Saggar sold 20,000 shares of Liquidia stock. The stock was sold at an average price of $27.85, for a total transaction of $557,000.00.

Liquidia Stock Up 1.9%

Liquidia stock opened at $26.09 on Friday. The company’s 50-day moving average price is $24.49 and its two-hundred day moving average price is $19.84. The company has a quick ratio of 2.41, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The stock has a market cap of $2.27 billion, a P/E ratio of -18.12 and a beta of 0.12. Liquidia Corporation has a twelve month low of $9.71 and a twelve month high of $29.94.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. The company had revenue of $54.34 million during the quarter, compared to analysts’ expectations of $18.86 million. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The company’s quarterly revenue was up 1106.7% on a year-over-year basis. As a group, analysts expect that Liquidia Corporation will post -1.51 EPS for the current year.

Institutional Investors Weigh In On Liquidia

A number of large investors have recently bought and sold shares of the company. JW Asset Management LLC bought a new position in Liquidia in the 3rd quarter valued at about $2,501,000. GSA Capital Partners LLP acquired a new stake in shares of Liquidia during the 3rd quarter worth approximately $878,000. Skandinaviska Enskilda Banken AB publ bought a new position in Liquidia in the third quarter valued at approximately $30,000. Vanguard Group Inc. increased its stake in Liquidia by 10.2% in the third quarter. Vanguard Group Inc. now owns 3,961,217 shares of the company’s stock valued at $90,078,000 after acquiring an additional 367,659 shares during the last quarter. Finally, Caprock Group LLC acquired a new position in Liquidia during the third quarter valued at approximately $37,114,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Liquidia in a report on Monday, November 3rd. Raymond James Financial restated a “strong-buy” rating and issued a $47.00 price target on shares of Liquidia in a research note on Tuesday. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a research report on Saturday. Needham & Company LLC boosted their price objective on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Finally, HC Wainwright increased their target price on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.56.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).